Expert Interview
A Second View: Examining the potential of Arvinas' Novel PROTAC Degrader Bavdegalutamide (ARV-110) in prostate cancer
Ticker(s): ARVNInstitution: University of Minnesota (formerly Hopkins)
- Associate Director for Translational Research at the Masonic Cancer Center & Director of Genitourinary Oncology Hematology, Oncology, and Transplantation) at the University of Minnesota Medical School.
- Clinical interest is the management of prostate cancer and other genitourinary malignancies.
- Research focuses on developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches.
Roughly how many patients with prostate cancer do you currently manage?
Added By: c_adminCan you tell us a little bit about your professional background and your clinical practice?
What could explain why this drug works in the mutational signature cases but not the wild-type receptor cases?
If you had 128 patients instead of 28, would you still see a 46% response? And how many patients have this particular mutation status?
They mentioned running a Phase 3 trial specifically targeting patients with the mutation signature. Are you optimistic that will succeed?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
